This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Stephenson and a team of researchers from various academic and pharmaceutical institutions, including the University of Virginia School of Medicine. Maelys Touya was an employee of Lundbeck LLC, and Lambros Chrones was an employee of Takeda Pharmaceuticals U.S.A., The study was authored by Judith J. Additionally, Anita H.
However, rather than people becoming enraged and politically engaged to change carcinogenic environments, an extremely powerful medical-pharmaceutical industrial complex has controlled the societal narrative to focus—not on eliminating environmental-societal causes of cancer—but on expensive cancer treatments. between 1990 and 2019.”
Community rating is a method for pricing insurance that pools policyholders within a geographic area into a single risk pool (a “community”) and charges them the same premium regardless of health, gender or other factors. These changes create uncertainty for insurers that they are expected to oï¬set with higher premium rates.
V-BID V alue-Based Insurance Design (V-BID) is about shifting the conversation from how much to how well. Here's how the Center for Value-Based Insurance Design describes applying V-BID to specialty medication. The arrangement would have been the first agreement with a manufacturer for outcomes-based pricing.
He also co-founded Hobbs/Herder Insurance Marketing Systems and Hobbs/Herder Training, among others. She successfully started, scaled and sold businesses in service, retail, e-commerce and product manufacturing in addition to creating a vast real estate portfolio as a flipper and investor.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content